USE OF DAPAGLIFLOZIN FOR HEART FAILURE WITH REDUCED EJECTION FRACTION IN ITALIAN CLINICAL PRACTICE (EVOLUTION-HF ITALY): INTERIM ANALYSIS AT 6 MONTHS OF FOLLOW-UP
Anno:
2024
Background. Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2i) approved for the treatment of Heart Failure (HF); however, real-world data on the use of dapagliflozin in the setting of HF with reduced Ejection Fraction (HFrEF) are scarce. EVOLUTION-HF Italy is part of a wider initiative aimed at filling these gaps…